PRGO
Perrigo Company plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IE
$14.92
+4.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1B | 4.3B | 4.4B | 4.7B | 4.5B |
| Cost of Revenue | 2.8B | 2.8B | 2.8B | 3.0B | 3.0B |
| Gross Profit | 1.4B | 1.5B | 1.5B | 1.7B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 95.0M | 95.4M | 112.2M | 122.5M | 123.1M |
| SG&A Expense | 331.4M | 526.5M | 1.1B | 1.3B | 1.2B |
| General & Admin Expense | (125.2M) | — | 468.0M | 522.3M | 512.3M |
| Selling & Marketing Expense | 456.6M | 526.5M | 644.6M | 752.3M | 697.8M |
| Other Expenses | 738.0M | 529.3M | 205.0M | 131.4M | 43.3M |
| Total Operating Expenses | 1.2B | 1.2B | 1.4B | 1.5B | 1.4B |
| Cost and Expenses | 3.9B | 3.9B | 4.3B | 4.5B | 4.4B |
| Operating Income (EBIT) | 215.0M | 343.3M | 112.9M | 151.9M | 78.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 163.1M | 162.5M | 187.8M | 173.8M | 156.0M |
| Net Interest Income | (163.1M) | (162.5M) | (187.8M) | (173.8M) | (156.0M) |
| Other Non-Op Income/Expense | (1.8B) | (1.6B) | (193.6M) | (160.2M) | (218.0M) |
| Non-Operating Income (excl Interest) | 1.7B | 1.5B | 5.8M | (13.6M) | 62.0M |
| EBT (Pre-Tax Income) | (1.6B) | (1.3B) | (80.7M) | (8.3M) | (139.1M) |
| Income Tax Expense | 90.7M | 104.4M | 80.0M | (3.9M) | (8.2M) |
| Bottom Line | |||||
| Net Income | (1.7B) | (1.4B) | (171.8M) | (12.7M) | (140.6M) |
| Earnings from Cont. Ops | (1.7B) | (1.4B) | (160.7M) | (4.4M) | (130.9M) |
| Earnings from Discont. Ops | (31.6M) | (23.1M) | (11.1M) | (8.3M) | (9.7M) |
| Bottom Line Net Income | (1.7B) | (1.4B) | (171.8M) | (12.7M) | (140.6M) |
| Per Share | |||||
| Basic EPS | ($12.51) | ($10.29) | ($1.25) | ($0.09) | ($0.97) |
| Diluted EPS | ($12.52) | ($10.29) | ($1.25) | ($0.09) | ($0.97) |
| Revenue Per Share | $29.80 | $30.71 | $31.83 | $34.41 | $33.10 |
| Shares | |||||
| Basic Shares Outstanding | 139.1M | 138.5M | 137.4M | 135.3M | 134.5M |
| Diluted Shares Outstanding | 139.6M | 138.5M | 137.4M | 135.3M | 134.5M |
| Profitability Metrics | |||||
| EBITDA | (1.2B) | (797.9M) | 433.0M | 525.0M | 355.5M |
| D&A | 224.4M | 337.5M | 325.9M | 359.5M | 338.6M |
| EBIT | (1.4B) | (1.1B) | 107.1M | 165.5M | 16.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026